The 2026 federal hemp redefinition, explained

Congress folded the change into an appropriations act: Public Law 119-37, enacted November 12, 2025, whose Section 781 amends the definition of hemp in Section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o), effective 365 days after enactment, November 12, 2026. Three moves matter to marketers. First, the familiar 0.3 percent plant cap survives but the metric changes from delta-9 THC to total tetrahydrocannabinols, including tetrahydrocannabinolic acid, which is the measurement that made high-THCA flower marketable as hemp. Second, the law excludes from hemp any final hemp-derived cannabinoid product that exceeds 0.4 milligrams combined total THC per container. Third, it excludes any final product containing cannabinoids not capable of being naturally produced, or synthesized or manufactured outside the plant. A product outside the definition is not a differently regulated hemp product; it reverts to Controlled Substances Act treatment. The Act also directs the FDA to publish cannabinoid lists within 90 days of enactment, and no implementing lists are published as of this page's drafting, so part of the compliance picture is still forming.

The most common sentence in hemp e-commerce, some version of 100 percent federally legal, Farm Bill compliant, legal in all 50 states, is exactly the copy this law puts on a clock. The claim may be accurate today. On November 12, 2026, for any product whose container carries more than 0.4 milligrams of total THC, it becomes false, and deceptive hemp and CBD marketing is independently reachable under FTC Act Section 5, which does not require a cannabis-specific rule to act on an untrue legality claim. The scanner treats this as an advisory flag rather than a present prohibition: a hit means confirm the product's total-THC content per container against the new definition and update the claim before the effective date, not that the sentence is unlawful this morning. The point of the flag is that legality claims date, and this one has a printed expiration.

The second exclusion reaches the intoxicating-hemp shelf directly. Delta-8, delta-10, THC-O, HHC, and THCP products are commonly produced by conversion or synthesis, typically from CBD, and cannabinoids synthesized or manufactured outside the plant fall outside the amended hemp definition on the effective date, on top of the 0.4 milligram per-container cap that most intoxicating products exceed on their own. Marketing that positions these as hemp products, and therefore as federally lawful, is the copy at risk. Which specific cannabinoids land on which side is partly an FDA question the Act's directed lists have not yet answered, so the honest posture for a brand or an agency is to confirm each cannabinoid's status and the product's reformulation or relabeling timeline with counsel rather than to assume the current shelf survives the definition change.

This is a formulation and labeling project wearing a marketing deadline. A copy scan can catch the claims side: blanket legality language, Farm-Bill framing, and synthesized-cannabinoid positioning all surface with the citation attached. What a copy scan cannot answer is whether your product exceeds 0.4 milligrams total THC per container, which is a lab and formulation question, or how the FDA's forthcoming cannabinoid lists will treat your inputs. So the sequence is: inventory every product's total-THC content per container against the new definition, inventory every legality claim in your copy, ads, and packaging against that result, and put the reformulation, relabeling, and rewrite on a timeline that finishes before the effective date. Your state's cannabis or hemp rules apply on top of all of it; the state guides in this cluster cover the four we compile.

The scanner reads the legality claim and the cannabinoid positioning together; the pair below is the before-and-after of the same product page.

Pre-Trip is a rigorous screen, not legal advice. Counsel decides; we help you arrive prepared.